Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221377 | 1.00 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL4175709 | 0.96 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL19953615 | 0.93 | PTGS2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL8289160 | 0.93 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL4191070 | 0.92 | PTGS2 (0.42) | PTGS2PTGS1 | |
| SCHEMBL4197238 | 0.92 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL4179563 | 0.92 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL4185483 | 0.90 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL4190197 | 0.89 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL8289110 | 0.89 | MCHR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090492-A1 | TUMOR-ACTIVATED CELL ENGAGERS AND METHODS OF USE THEREOF | Xilio Development, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116940-A1 | MASKED CYTOKINE POLYPEPTIDES | XILIO DEV INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | XILIO DEV INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114159421-A | Pharmaceutical composition comprising dimethyl fumarate | 阿尔米雷尔有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022040058-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2022-02-10 | — | — | US | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | MAFG, MAFK, ACP3 | PTGS2 4070/4885PTGS1 3864/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | PTGS2 1827/4885PTGS1 1014/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PTGS2 2731/4885PTGS1 3480/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885PTGS1 16/4885 |
| US-20260116940-A1 | MASKED CYTOKINE POLYPEPTIDES | TNFRSF9, IL36G, TNFSF11 | PTGS2 2418/4885PTGS1 2106/4885 |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | PTGS2 1678/4885PTGS1 1175/4885 |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | ABL1, BTK, LYN | PTGS2 3974/4885PTGS1 3564/4885 |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | SPPL2B, SPPL2A, CTSL | PTGS2 2186/4885PTGS1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.